Current Issues in the Design and Analysis of Stepped Wedge Trials

Por Hughes, James P., Granston, Tanya S., Heagerty, Patrick J.
Publicado no Contemp Clin Trials (2015)

Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies

Por Verstovsek, Srdan, Odenike, Olatoyosi, Singer, Jack W., Granston, Tanya, Al-Fayoumi, Suliman, Deeg, H. Joachim
Publicado no J Hematol Oncol (2016)

The Relevance of Different Methods of Calculating the Ankle-Brachial Index: The Multi-Ethnic Study of Atherosclerosis

Por Allison, Matthew A., Aboyans, Victor, Granston, Tanya, McDermott, Mary M., Kamineni, Aruna, Ni, Hanyu, Criqui, Michael H.
Publicado em 2010

Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis

Por Komrokji, Rami S., Seymour, John F., Roberts, Andrew W., Wadleigh, Martha, To, L. Bik, Scherber, Robyn, Turba, Elyce, Dorr, Andrew, Zhu, Joy, Wang, Lixia, Granston, Tanya, Campbell, Mary S., Mesa, Ruben A.
Publicado no Blood (2015)

Metabolic Syndrome, Diabetes, and Incidence and Progression of Coronary Calcium: The Multiethnic Study of Atherosclerosis (MESA)

Por Wong, Nathan D., Nelson, Jennifer C, Granston, Tanya, Bertoni, Alain G., Blumenthal, Roger S., Carr, J. Jeffrey, Guerci, Alan, Jacobs, David R., Kronmal, Richard, Liu, Kiang, Saad, Mohammed, Selvin, Elizabeth, Tracy, Russell, Detrano, Robert
Publicado em 2012